Item 9 Labs Past Earnings Performance
Past criteria checks 0/6
Item 9 Labs's earnings have been declining at an average annual rate of -42.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been declining at an average rate of 17.4% per year.
Key information
-42.8%
Earnings growth rate
-37.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -17.4% |
| Return on equity | -59.0% |
| Net Margin | -157.6% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Item 9 Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 20 | -31 | 18 | 0 |
| 31 Mar 23 | 20 | -31 | 18 | 0 |
| 31 Dec 22 | 21 | -31 | 19 | 0 |
| 30 Sep 22 | 22 | -31 | 19 | 0 |
| 30 Jun 22 | 24 | -22 | 19 | 0 |
| 31 Mar 22 | 26 | -17 | 17 | 0 |
| 31 Dec 21 | 25 | -13 | 15 | 0 |
| 30 Sep 21 | 22 | -11 | 13 | 0 |
| 30 Jun 21 | 18 | -9 | 9 | 0 |
| 31 Mar 21 | 14 | -10 | 7 | 0 |
| 31 Dec 20 | 10 | -11 | 6 | 0 |
| 30 Sep 20 | 8 | -12 | 6 | 0 |
| 30 Jun 20 | 7 | -13 | 5 | 0 |
| 31 Mar 20 | 6 | -12 | 6 | 0 |
| 31 Dec 19 | 6 | -11 | 6 | 0 |
| 30 Sep 19 | 5 | -10 | 5 | 0 |
| 30 Jun 19 | 4 | -2 | 3 | 0 |
| 31 Mar 19 | 3 | -2 | 2 | 0 |
| 31 Dec 18 | 2 | -1 | 1 | 0 |
| 30 Sep 18 | 1 | -1 | 1 | 0 |
| 30 Sep 17 | 0 | 0 | 0 | 0 |
Quality Earnings: INLB is currently unprofitable.
Growing Profit Margin: INLB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if INLB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare INLB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: INLB has a negative Return on Equity (-58.99%), as it is currently unprofitable.